Molecular Diagnostics

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Infectious Diseases Testing
• Pharmacogenomics
• Cancer Screening

II. EXECUTIVE SUMMARY

1. Industry Overview

• Global Market Outlook
• Molecular Diagnostics - The Fastest Growing Medical Diagnostic Technology
• New Applications Hold Promising Potential
• Automated Systems - Prime Target
• Infectious Disease Testing Drives the Diagnostics Market
• The Future in Store

2. A Review of Medical Diagnostics Market

• Clinical Diagnostics Industry - Trends and Tendencies
• Table 1: Worldwide In Vitro Diagnostics (IVD) Market (2005 & 2006)- Percentage Breakdown by Value Sales for Immunochemistry, Diabetes, Clinical Chemistry, Point-of-care testing, Molecular Diagnostics, Hematology, Coagulation, Urinalysis, and Others (includes corresponding Graph/Chart)
• Table 2: Leading Players in the Worldwide In Vitro Diagnostics (IVD) Market (2005) - Percentage Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Johnson & Johnson, Bayer Diagnostics, Beckman Coulter, Dade Behring, and Others (includes corresponding Graph/Chart)
• Table 3: Leading Players in the Worldwide Molecular Diagnostics Market (2006) - Percentage Breakdown by Value Sales for Roche Diagnostics, Chiron, Bayer Diagnostics, GenProbe, Abbott Laboratories, Becton Dickinson, and Others (includes corresponding Graph/Chart)
• Diagnostic Tests - Classification
• Table 4: Leading Players in the Worldwide Genetic Testing Market (2006) - Percentage Breakdown by Value Sales for Roche Diagnostics /Affymetrix, Abbott Laboratories, Bio-Rad Laboratories, and Others(includes corresponding Graph/Chart)
• Nucleic Acid Diagnostics Market - An Overview
• Molecular Diagnostics - Growth Drivers
• Molecular Diagnostics - A Replacement and Enabling Technology
• Molecular Diagnostics for Lymphoid Malignancies

3. Competitive Dynamics in the Molecular

Diagnostics Market

• Key Players and Their Technologies
• The Top Tier
• Mid-Sized and Small Companies

4. Market Trends & Issues

• Market Consolidations on the Way to Integrate in Vivo and in Vitro Diagnostics
• Global Molecular Diagnostics on High Growth Curve
• Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market
• Towards Tailoring the Right Treatment for the Right Disease
• Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes
• Molecular Diagnostics and Intellectual Property
• Business Opportunities in the Offing
• Challenges Facing the Molecular Diagnostic Market
• Medical Training and Practice Challenges
• Shortcomings to Overcome
• Limited Reimbursements by Third Party Payers - A Stumbling Block
• Hurdles All the Way for Companies Eyeing Molecular Diagnostics
• Product Marketing - Key to Commercial Success
• Integration of Molecular Diagnostics into Therapeutics
• Molecular Diagnostics - Moving from Centralization to Decentralization
• Migrating to Decentralized Format
• Going Ahead with Decentralization

5. Product & Technology Overview

• Molecular Diagnostics - Definition & Scope
• Molecular Diagnostics - Impact on Healthcare
• Utility of Molecular Diagnostic Tests
• Background of Molecular Diagnostics
• Major Molecular Diagnostics Company Products
• Major Test Launches in Molecular Diagnostics
• Unabated Developments in Molecular Diagnostics Technology
• Signal Amplification Technologies
• PCR - New Developments
• Major Applications of Real-Time PCR
• Quantitative Real-Time PCR for Molecular Diagnostics
• Signal Detection and Quantification
• Quantitative Real-Time RT-PCR Analysis
• Applications of Quantitative Real-Time PCR Analysis
• Non-PCR Methods
• Other Signal Amplification Technologies
• DNA Probe Based Products
• Direct Detection of Specific Nucleic Acid Sequences
• Nucleic Acid Amplification and Detection
• DNA Sequencing and Gene Detection
• Arrays of Immobilized Probes (DNA Chips) in Gene Detection
• RNA Diagnostics
• Complementary Molecular Diagnostic Technologies
• Fluorescent in situ hybridization (FISH)
• DNA Biochips / Microarrays
• Biosensors
• Proteomic Technologies for Molecular Diagnostics
• Nanotechnology for Molecular Diagnostics
• Technologies on the Anvil
• Haplotype Analysis - A Distant Possibility
• Chronic Multi-Gene Defects Now Diagnosable

6. An Insight into Applications of Molecular

Diagnostics

• Infectious Diseases Testing
• Activity in the Field
• Identifying Multidrug Resistance
• Infectious Disease Treatment Monitoring
• Other Infectious Diseases Applications
• Genetic Disease Testing Applications
• Pharmacogenomics - Prognosis Based on Genomics
• Cancer Screening & Diagnosis
• Molecular Tests Lead the Way for Cancer IVD Market Growth
• Table 5: Worldwide Cancer Diagnostic Testing Market (2006): Percentage Breakdown of Value Sales for Immunoassays, Histology (IHC/ISH), Pap Testing, Flow Cytometry, Prostate-Specific Antigen, Molecular Assays, and Fecal Occult Blood Test (includes corresponding Graph/Chart)
• Other Testing Applications

7. Product Developments/Introductions

• TMD Launches Test for K-ras Mutations in Colorectal Cancer Patients
• CombiMatrix Releases Updated Version of Constitutional Genetic Array Test
• Myriad Introduces TheraGuide 5-FU
• CMDX Unveils First HemeScan(tm) Prognostic
• CombiMatrix Introduces HemeScan(tm) MDS
• Genzyme Rolls Out Two New Molecular Tests
• Dade Behring Launches The Quadriga BeFree
• BD Diagnostics Introduces The BD Viper System
• Genzyme Introduces P53 Mutation Analysis
• CombiMatrix Molecular Diagnostics Rolls Out A New Melanoma Test
• Qiagen Launches Fast Cycling PCR Product Line
• Genzyme Releases Molecular Assay for Colorectal Cancer Patients
• Roche Diagnostics Launches LightCycler 480 System
• Roche Diagnostics Introduces AmpliChip CYP450 Test
• SEQUENOM Unveils iPLEX(tm)
• SEQUENOM Develops a Novel Process
• Cerner Corp Develops Cerner Millennium(R) PathNet Helix(TM)
• Roche Diagnostics Launches Amplicor HPV Test
• Gen-Probe Launches Procleix Ultrio Assay in Europe
• Gen-Probe Launches TIGRIS(r)DTS(tm) System
• BD Biosciences Introduces BD QZyme(tm) Assay
• Epoch Biosciences Releases MGB Eclipse(tm)
• QIAGEN Unveils BioRobot MDx DSP Device
• Digene Unveils DNAwithPap
• Exact Sciences Launches Non-Invasive Test for Colorectal Cancer
• TDT Introduces GCC-B1 Blood Test to Detect Colorectal Cancer
• AcroMetrix Joins Hands with Nabi to Introduce ViroSure
• Orchid Cellmark Introduces DNA Express Service
• Roche Develops New IVD Real-Time PCR Instrument
• Nanogen Rolls Out First Ever ASR
• Digene Introduces Hybrid Capture
• Digene' s Hybrid Capture 2 HPV DNA Test to Effectively Identify Cervical Cancer
• PGD to Eliminate Human Eggs Affected with Alzheimer' s Disease
• Esoterix Introduces New HCV Testing Program
• Gen-Probe Releases New APTIMA Combo 2 Assay
• Nycomed' s NeoSpect to Identify Suspected Lung Cancer
• DNAPrint Introduces New Services to Assist Forensic Market
• IMBG Develops an Efficient Procedure to Treat Diseases

8. Recent Industry Activity

• Vermillion, Johns Hopkins Ink Agreements to Develop Molecular Diagnostic Tests
• Beckman Coulter Inks Licensing Agreements with National University of Ireland
• Roche Takes over BioVeris
• Siemens Acquires Dade Behring
• DiagnoCure Acquires Catalyst Oncology
• Burrill & Co Takes over Expression Diagnostics
• Solis Acquires Bertrand
• ParagonDx LLC Purchases Gentris Diagnostics
• Beckman Collaborates to Discover CVD Symptoms
• Exiqon to Take over Oncotech
• Roche to Acquire Ventana
• Qiagen Merges with Digene
• Qiagen & Bio One Capital Collaborates
• AGT & MAL Signs MoU
• Qiagen Obtains Licenses to Real-Time PCR
• Cepheid Purchases Sangtec
• Source MDx Collaborates with Pfizer
• Nanosphere Receives FDA Clearance for Second Molecular Diagnostic Test
• QIAGEN Acquires eGene
• Quest Diagnostics Acquires AmeriPath
• Mayo and ILMN Team up to Develop Molecular Diagnostics for Complex Diseases
• CHEO and ILMN Team up to Develop Molecular Diagnostics for Newborn Screening
• Siemens Medical Solutions USA Sets Up Siemens Medical Solutions Diagnostics
• Novartis Acquires Chiron
• Quest Diagnostics Acquires Focus Diagnostics
• Becton Dickinson Acquires GeneOhm
• Iris International Acquires Leucadia Technologies
• Predicant Biosciences Acquires Pathwork Informatics
• AmeriPath Acquires Rose Pathology Associates
• Nanogen Acquires Amplimedical' s Diagnostics Division
• Nanogen Acquires Immunoassay Test Business of Spectral Diagnostics
• Fisher Scientific Acquires Athena
• Qiagen Acquires Genaco
• Bio-Rad Acquires Blackhawk BioSystems
• IRIS International Acquires Leucadia Technologies
• Qiagen Acquires Shenzhen PG Biotech
• Qiagen Acquires Artus GmbH
• Nanogen and Fisher Increases Agreement Tenure
• Qiagen Signs An Agreement with Gentra
• Qiagen Inks an Agreement with VLA
• Stratagene Signs an Agreement with AROS
• Bayer Inks an Agreement with Hamilton Company
• Prodesse and Invitrogen Sign a Pact
• Illumina Forms Collaboration with ReaMetrix
• PerkinElmer Signs an Agreement with Jacobi Medical
• UniPath and Roche Diagnostics Sign an Accord
• Qiagen Alliances with Eppendorf
• Olympus and Cangen Extends their Research Collaboration
• Toppan, Shimadzu and Third Wave Collaborate to Develop A POC Molecular Diagnostic Instrument
• Focus Diagnostics Signs an Agreement with Stratagene
• Innogenetics Inks an Agreement with Roche Diagnostics
• The University of Goettingen, Bruker Daltonik and PANATecs Collaborate to Develop New Molecular Diagnostic Assays for Rheumatoid Arthritis
• Focus Diagnostics Enters into an Agreement with Luminex
• QIAGEN Expands Strategic Alliance with Protedyne
• Specialty Laboratories Teams Up with SEQUENOM and Siemens
• Gen-Probe Enters into a Licensing Agreement with Corixa
• Gen-Probe Inks a Supply and Purchase Agreement with F. Hoffmann-La Roche
  • Gen-Probe Enters into a Licensing Agreement with AdnaGen
  • Roche Establishes New Polymerase Chain Reaction (PCR) Manufacturing Center
  • Ambion Establishes a Subsidiary in Japan
  • Gen-Probe Gains FDA Approval for APTIMA(r)
  • Blood Center of Southeastern Wisconsin Adopts Ambion' s Signature(tm) CF 2.0 ASR
  • Orchid Biosciences, Inc. Becomes Orchid Cellmark Inc
  • Roche Acquires IGEN International
  • GE Takes Over Amersham Plc
  • Nanogen Acquires SYN.X PHARMA
  • Nanogen Merges with Epoch Biosciences
  • Sequenom Enters into Collaboration with Siemens
  • TMD Joins Hands with University of Texas
  • GE Global and Two other Companies Enters into a Joint Research Collaboration
  • Third Wave and BML Extend Partnership to Promote Molecular Diagnostic Tests
  • ViroLogic Signs an Agreement with ACLARA
  • Abbott and BioGenex Sign an Agreement
  • Novation Signs a Pact with Bayer Diagnostics
  • Osmetech Enters into a Licensing Agreement with LGC Limited
  • Licensing Agreement between DxS Ltd and Sangtec Molecular Diagnostics
  • EraGen Biosciences Strikes a Deal with Inter Medico
  • Nanogen Bags Patent for Molecular Diagnostics and Optical Waveguides Systems
  • Gen-Probe Secures Regulatory Approval for PROCLEIX (r) ULTRIO(tm) Assay
  • Gen-Probe Bags FDA Approval to Use TIGRIS DTS System for STD Testing
  • Gen-Probe Acquires Majority Stake in MLT
  • AmeriPath in Strategic Alliance with Roche
  • Abbott and Promega to Offer Nucleic Acid Extraction Products
  • Ambion RNA to Offer Services Through BBI
  • STMicroelectronics Inks an Agreement with Mobidiag
  • BBI Contracts with IDS
  • Focus to Assist FDA in Evaluation of Antimicrobial Resistance
  • Bayer Acquires Rights to Detect HCV and HIV Antibodies
  • Cenetron in Strategic Alliance with Roche
  • Saint Luke' s Health System in Alliance with Roche
  • US LABS Adds Gene Expression Profiling Capabilities on (FFPE) Tissue
  • Bayer Acquires Visible Genetics
  • Qiagen Enters into an Agreement with RMS
  • Dabur Starts a New Molecular Diagnostic Lab
  • Roche Gains Rights for Cervical-Cancer Testing Market
  • Ventana Acquires License From MDI
  • Genzyme Genetics Gains Rights for Genzyme Molecular' s Cancer Diagnostics
  • Abbott in Strategic Alliance with Celera
  • MDI and DiagnoCure Join Hands to Integrate ImmunoCyt/uCyt with InPath
  • MDI and PMI to Jointly Promote Lung Cancer Detection System
  • MDI in Agreement with Esoterix
  • MDI to Expand Product Base in China
  • Abbott and Tecan to Offer Devices for Molecular Diagnostic Assays
  • Invirion Extends Licensing Agreement with MDI
  • Ambion RNA Grants License to Celera
  • Morewood and IT&M to Introduce New Micro Array System
  • Ambion RNA Constructs New Manufacturing Facility
  • LabCorp Teams up with Celera
  • Athena Launches New DNA Testing for TSC
  • Genezyme Genetics Expands Cancer Testing Services
  • Promega Teams Up with Abbott
  • ChromaVision and Ventana Join Hands to Market Testing Process that Identifies HPV
  • OraSure in Agreement with Abbott
  • Nanogen and Bionomics to Jointly Develop IVD for Epilepsy
  • DiagnoCure and Compugen Join Hands to Develop Tests to Identify Epithelial Cancers
  • OraSure Gets FDA Approval for OraQuick Rapid HIV-1 Test
  • Ampersand and Accumed Merged to Form MDI
  • Abbott Acquires Vysis
  • Millennium and Abbott Forge 5-Year Drug Deal
  • Bode Enters into Agreement to Undertake DNA Testing
  • BD Contracts with TriPath to Develop Molecular Diagnostics
  • TriPath Installs New Interactive System
  • Archemix in Strategic Alliance with RPI
  • AmeriPath Strengthens Relationship with Genomics Collaborative
  • Cepheid and Infectio Join Hands to Form Aridia
  • Myriad Enters into Agreement with NCI
  • Nanogen Gains Further Rights for Electronic Microarray Technology

9. Focus on Select Global Players

• Abbott Laboratories (US)
• Abbott Molecular
• Applera Corporation (US)
• Celera (US)
• Biomerieux (France)
• CytoCore Inc (US)
• GE Healthcare (US)
• Gen-Probe Inc (US)
• Genzyme Corporation (US)
• Genzyme Genetics (US)
• MiraiBio, Inc. (US)
• Nanogen (US)
• Novartis Vaccines & Diagnostics, Inc. (US)
• QIAGEN N. V (The Netherlands)
• Digene Corporation (USA)
• Quest Diagnostics Inc. (US)
• Roche Diagnostics (Switzerland)
• Siemens Healthcare Diagnostics (US)
• Tecan Group Ltd. (Switzerland)

10. Global Market Perspective

• Table 6: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 7: World Long-term Projections for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 8: World 10-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2003, 2008 & 2012(includes corresponding Graph/Chart)
• Table 9: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 10: World Long-term Projections for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 11: World 10-Year Perspective for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 12: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 13: World Long-term Projections for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 14: World 10-Year Perspective for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 15: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Cancer Screening) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 16: World Long-term Projections for Molecular Diagnostics (Cancer Screening) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 17: World 10-Year Perspective for Molecular Diagnostics (Cancer Screening) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. United States

• A. Market Analysis
  • A Precursor to the Molecular Diagnostics Market in the US
  • Molecular Diagnostics Heavily Tied to Proteomics and Genomics
  • Burgeoning Potential for Genetic Testing
  • Regulatory Environment
  • Regulations Out for Molecular Diagnostic Testing of HPV
  • Limited Reimbursements - A Major Hindrance
  • Key Players
  • Product Launches
  • Strategic Developments
• B. Market Analytics
  • Table 18: US Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 19: US Long-term Projections for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 20: US 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, andCancer Screening Markets for 2003, 2008 & 2012(includes corresponding Graph/Chart)

2. Canada

• A. Market Analysis
  • Strategic Developments
• B. Market Analytics
  • Table 21: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 22: Canadian Long-term Projections for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart
  • Table 23: Canadian 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Strategic Developments
• B. Market Analytics
  • Table 24: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 25: Japanese Long-term Projections for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 26: Japanese 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Insight into Molecular Diagnostics Markets in Europe
  • Table 27: European Molecular Diagnostics Market (2006) - Market Shares of Leading Players by Value Sales for Roche Diagnostics, Abbott Diagnostics, Bayer Diagnostics, Becton Dickinson, Digene Diagnostics, BioMerieux and Others (includes corresponding Graph/Chart)
  • Product Launches
• B. Market Analytics
  • Table 28: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 29: European Long-term Projections for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 30: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 31: European Long-term Projections for Molecular(includes corresponding Graph/Chart) Diagnostics by Product Segment -Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 32: European 10-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 33: European 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. France

• A. Market Analysis
  • bioMerieux - A Key French Player
  • Strategic Development
• B. Market Analytics
  • Table 34: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 35: French Long-term Projections for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 36: French 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. Germany

• Market Analysis
• Table 37: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 38: German Long-term Projections for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 39: German 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. Italy

• Market Analysis
• Table 40: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 41: Italian Long-term Projections for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 42: Italian 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. United Kingdom

• A. Market Analysis
  • Product Launch
  • Strategic Development
• B. Market Analytics
  • Table 43: UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 44: UK Long-term Projections for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 45: UK 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Rest of Europe

• A. Market Analysis
  • Key Players
  • Product Launches
  • Strategic Developments
• B. Market Analytics
  • Table 46: Rest of Europe Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 47: Rest of Europe Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 48: Rest of Europe 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Asia-Pacific

• A. Market Analysis
  • Indian Diagnostic Market
  • Strategic Developments
• B. Market Analytics
  • Table 49: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 50: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 51: Asia-Pacific 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

6. Rest of World

• Market Analysis
• Table 52: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 53: Rest of World Long-term Projections for Molecular Diagnostics by Product Segment - Infectious Disease Testing, Pharmacogenomics and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 54: Rest of World 10-Year Perspective for Molecular Diagnostics by Product Segment - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)